Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II. Open-Label, Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects.

Next Previous
Search
Trial Profile

A Phase I/II. Open-Label, Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Orteronel (Primary) ; Prednisone
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors Takeda Oncology

Most Recent Events

  • 13 Jun 2013 Planned end date changed from 1 Feb 2013 to 1 Mar 2015 as reported by ClinicalTrials.gov.
  • 23 Jan 2013 Planned end date changed from 1 Aug 2014 to 1 Feb 2013 as reported by ClinicalTrials.gov.
  • 26 Apr 2012 Planned end date changed from 1 Mar 2013 to 1 Aug 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top